There was no substantial difference in the FNR estimate by tumor subtype: 0% (95% CI 0–30%) for HR+/HER2−, 7% (95% CI 1–30%) for HER2+ disease, and 0% (95% CI 0–50%) for TNBC, with very small sample sizes and resulting wide confidence intervals. Here, ERBB2 is linked to neoplasm.